Contraceptive Pills and Retinal Vascularization

Study Overview
=================
Brief Summary
-----------------
The main hypothesis is the taking of combined 1st and 2nd generation or 3rd and 4th generation oral contraceptives is associated with a change in retinal micro-vascularization compared to the absence of combined oral contraceptive intake. Women of childbearing age will be recruited during their ophthalmologic consultation at the Rothschild Foundation, an OCT-A will be realized and data relating to their medical and ophthalmologic history and their oestro-progestative contraceptive intake will be collected. The objective is to find an association between retinal vascular density and combined oral contraceptives intake.

Official Title
-----------------
Contraceptive Pills and Retinal Vascularization (Piluret)

Conditions
-----------------
Combined Oral Contraceptives Intake

Intervention / Treatment
-----------------
* Diagnostic Test: OCT-A (optical coherence tomography)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria for the control group : No Estro-progestin contraceptive treatment (oral, transdermal) for at least 6 months for the cases under combined 1st and 2nd generation pills : Estro-progestin contraceptive treatment for at least 6 months for the cases under combined 3rd and 2th generation pills: Estro-progestin contraceptive treatment for at least 6 months Exclusion criteria: Menopausal woman Ametropia greater than + 3 hyperopia diopters or-3 myopia diopters Astigmatism greater than 2 dioptres Smoking patient (cigarette or e-cigarette) Caffeine intake within 2 hours prior to the OCT-A exam Any known retinal pathology Antecedent of deep vein thrombosis or deep arterial thrombosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| no contraceptive intake<br> | Diagnostic Test: OCT-A (optical coherence tomography)<br>* Included patients will have an OCT-A and will be questioned about their medical and ophthalmologic history, and their oestro-progestative contraceptive intake.<br>|
| combined 1st/2nd generation oral contraceptives intake<br> | Diagnostic Test: OCT-A (optical coherence tomography)<br>* Included patients will have an OCT-A and will be questioned about their medical and ophthalmologic history, and their oestro-progestative contraceptive intake.<br>|
| 3rd/4th generation combined oral contraceptives intake<br> | Diagnostic Test: OCT-A (optical coherence tomography)<br>* Included patients will have an OCT-A and will be questioned about their medical and ophthalmologic history, and their oestro-progestative contraceptive intake.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Density of retinal vascular Plexus (quantitative variable expressed as a percentage) using OCT-A. |  | At the inclusion consultation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
OCT-A, combined oral contraceptives